The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Targeted Therapies for Malignant Glioma: Progress and Potential
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the increased production of NO elicited by the statins reduced the activity of at least two proteins -Pgp/ABCB1 and BCRP/ABCG2 -that are involved in the apical extrusion of drugs in hCMEC/D3 cells (Tai et al., 2009) and in vivo (Declèves et al., 2006;Mercer et al., 2009;Robey et al., 2010).”
From The association of statins plus LDL receptor‐targeted liposome‐encapsulated doxorubicin increases in vitro drug delivery across blood–brain barrier cells (2012) · cites this paper as Mercer et al., 2009
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both tumour cells and BBB endothelial cells are rich in ATP-binding cassette (ABC) transporters, like P-glycoprotein (Pgp/ABCB1), multidrug resistance-related proteins (MRPs/ABCCs) and breast cancer resistance protein (BCRP/ABCG2) that extrude drugs from the luminal side of endothelial cells back into the blood and out of the tumour cells (Declèves et al., 2006;Mercer et al., 2009;Robey et al., 2”
From The association of statins plus LDL receptor‐targeted liposome‐encapsulated doxorubicin increases in vitro drug delivery across blood–brain barrier cells (2012) · cites this paper as Mercer et al., 2009
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, having no fenestrations and many tight junctions, the brain microvascular endothelium has high levels of drug efflux pumps of the ABC transporter family (Declèves et al., 2006;Mercer et al., 2009;Robey et al., 2010).”
From The association of statins plus LDL receptor‐targeted liposome‐encapsulated doxorubicin increases in vitro drug delivery across blood–brain barrier cells (2012) · cites this paper as Mercer et al., 2009
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Doxorubicin, for instance, is a very effective anticancer drug against glioblastoma cells in vitro, but since it is a substrate of Pgp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2, its delivery across the BBB is hampered and it is ineffective clinically at treating this tumour.”
From The association of statins plus LDL receptor‐targeted liposome‐encapsulated doxorubicin increases in vitro drug delivery across blood–brain barrier cells (2012) · cites this paper as Mercer et al., 2009
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Flagged first, then by citations
Research works printed but not linked: 64
- Percy, 1984 Jun, Hum Pathol, 15, 598, 10.1016/S0046-8177(84)80018-0 · DOI
- Kleihues, 1993 Jul, Brain Pathol, 3, 255, 10.1111/j.1750-3639.1993.tb00752.x · DOI
- Westphal, 2003 Apr, Neuro Oncol, 5, 79, 10.1093/neuonc/5.2.79 · DOI
- Stupp, 2005 Mar 10, N Engl J Med, 352, 987, 10.1056/NEJMoa043330 · DOI · Paper page
- Hegi, 2005 Mar 10, N Engl J Med, 352, 997, 10.1056/NEJMoa043331 · DOI · Paper page
- de Groot, 2007 Dec, Curr Opin Neurol, 20, 712, 10.1097/WCO.0b013e3282f15650 · DOI
- Citri, 2006 Jul, Nat Rev Mol Cell Biol, 7, 505, 10.1038/nrm1962 · DOI
- Humphrey, 1988 Apr 15, Cancer Res, 48, 2231
- Pelloski, 2007 Jun 1, J Clin Oncol, 25, 2288, 10.1200/JCO.2006.08.0705 · DOI
- Sarkaria, 2007 Mar, Mol Cancer Ther, 6, 1167, 10.1158/1535-7163.MCT-06-0691 · DOI
- Lassman, 2005 Nov 1, Clin Cancer Res, 11, 7841, 10.1158/1078-0432.CCR-05-0421 · DOI
- Tacken, 2007 Oct, Nat Rev Immunol, 7 (, 790, 10.1038/nri2173 · DOI
- Garcia de Palazzo, 1993 Jul 15, Cancer Res, 53, 3217
- Wikstrand, 1995 Jul 15, Cancer Res, 55, 3140
- Ekstrand, 1991 Apr 15, Cancer Res, 51, 2164
- Heimberger, 2005 Feb 15, Clin Cancer Res, 11, 1462, 10.1158/1078-0432.CCR-04-1737 · DOI
- Moscatello, 1997 Apr 15, Cancer Res, 57, 1419
- Ciesielski, 2005 Feb, Cancer Immunol Immunother, 54, 107, 10.1007/s00262-004-0576-y · DOI
- Sampson, 2008 Oct, Semin Immunol, 20, 267, 10.1016/j.smim.2008.04.001 · DOI
- Yajima, 2005 Aug 15, Clin Cancer Res, 11, 5900, 10.1158/1078-0432.CCR-05-0559 · DOI
- Barnett, 2007 Jun 15, Clin Cancer Res, 13, 3559, 10.1158/1078-0432.CCR-06-2430 · DOI
- Komata, 2002 Jan 21, Oncogene, 21, 656, 10.1038/sj.onc.1205072 · DOI
- Tsuda, 2002 Oct 21, Br J Cancer, 87, 1006, 10.1038/sj.bjc.6600593 · DOI
- Yamada, 2003 Oct, J Neurosurg, 99, 738, 10.3171/jns.2003.99.4.0738 · DOI
- Ventimiglia, 1992 Jan, J Neuroimmunol, 36, 41, 10.1016/0165-5728(92)90029-K · DOI
- Kurpad, 1995 Nov, Glia, 15, 244, 10.1002/glia.440150306 · DOI
- Hurwitz, 2004 Jun 3, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 · DOI · Paper page
- Giantonio, 2007 Apr 20, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305 · DOI · Paper page
- Vredenburgh, 2007 Feb 15, Clin Cancer Res, 13, 1253, 10.1158/1078-0432.CCR-06-2309 · DOI
- Batchelor, 2004 Jan, Neuro Oncol, 6, 21, 10.1215/S1152851703000218 · DOI
- Prados, 2006 Apr, Neuro Oncol, 8, 189, 10.1215/15228517-2005-010 · DOI
- Ostman, 2004 Aug, Cytokine Growth Factor Rev, 15, 275, 10.1016/j.cytogfr.2004.03.002 · DOI
- Wen, 2006 Aug 15, Clin Cancer Res, 12, 4899, 10.1158/1078-0432.CCR-06-0773 · DOI
- Dresemann, 2005 Oct, Ann Oncol, 16, 1702, 10.1093/annonc/mdi317 · DOI
- Reardon, 2005 Dec 20, J Clin Oncol, 23, 9359, 10.1200/JCO.2005.03.2185 · DOI
- Bihorel, 2006 Dec, Drug Metab Dispos, 34, 1945, 10.1124/dmd.106.010975 · DOI
- Knobbe, 2004 Dec, Acta Neuropathol, 108, 467, 10.1007/s00401-004-0929-9 · DOI
- Cloughesy, 2006 Aug 1, J Clin Oncol, 24, 3651, 10.1200/JCO.2006.06.2323 · DOI
- Chakravarti, 2004 May 15, J Clin Oncol, 22, 1926, 10.1200/JCO.2004.07.193 · DOI · Paper page
- Vivanco, 2002 Jul, Nat Rev Cancer, 2, 489, 10.1038/nrc839 · DOI
- Galanis, 2005 Aug 10, J Clin Oncol, 23, 5294, 10.1200/JCO.2005.23.622 · DOI
- Chang, 2005 Aug, Invest New Drugs, 23, 357, 10.1007/s10637-005-1444-0 · DOI
- Sawyers, 2006 Jul 20, N Engl J Med, 355, 313, 10.1056/NEJMcibr062354 · DOI
- da Rocha, 2002, Oncologist, 7, 17, 10.1634/theoncologist.7-1-17 · DOI
- Balendran, 2000 Nov 10, FEBS Lett, 484, 217, 10.1016/S0014-5793(00)02162-1 · DOI
- Hui, 2004 Dec 15, Cancer Res, 64, 9115, 10.1158/0008-5472.CAN-04-2740 · DOI
- Brandes, 1999 Feb, J Clin Oncol, 17, 645, 10.1200/JCO.1999.17.2.645 · DOI
- Spence, 2004 Oct, J Neurooncol, 70, 91, 10.1023/B:NEON.0000040837.68411.97 · DOI
- Graff, 2005 Aug 15, Cancer Res, 65, 7462, 10.1158/0008-5472.CAN-05-0071 · DOI
- Chinnaiyan, 2005 May 1, Int J Radiat Oncol Biol Phys, 62, 223, 10.1016/j.ijrobp.2004.12.088 · DOI
- Richter, 2001 Sep, J Cell Physiol, 188, 281, 10.1002/jcp.1131 · DOI
- Yang, 2001 May 15, Cancer Res, 61, 4010
- Debinski, 1995 Nov, Clin Cancer Res, 1, 1253
- Husain, 2003 Oct, J Neurooncol, 65, 37, 10.1023/A:1026242432647 · DOI
- Kioi, 2006 Jun, Technol Cancer Res Treat, 5, 239, 10.1177/153303460600500307 · DOI
- Kunwar, 2007 Mar 1, J Clin Oncol, 25, 837, 10.1200/JCO.2006.08.1117 · DOI · Paper page
- Chakravarti, 2002 Jan 1, Cancer Res, 62, 200
- Li, 2003 Nov 1, Cancer Res, 63, 7443
- Reardon, 2006 Feb 1, Clin Cancer Res, 12, 860, 10.1158/1078-0432.CCR-05-2215 · DOI
- Goudar, 2005 Jan, Mol Cancer Ther, 4, 101, 10.1158/1535-7163.101.4.1 · DOI
- Sandstrom, 2008 May, J Neurooncol, 88, 1, 10.1007/s11060-008-9527-3 · DOI
- de Bouard, 2007 Oct, Neuro Oncol, 9, 412, 10.1215/15228517-2007-024 · DOI
- Jane, 2006 Dec, J Pharmacol Exp Ther, 319, 1070, 10.1124/jpet.106.108621 · DOI
- Fine, 2007 Nov-Dec, Cancer J, 13, 349, 10.1097/PPO.0b013e31815b18db · DOI
Cited by
Sorted by citations
Chitosan–alginate 3D scaffolds as a mimic of the glioma tumor microenvironment
Kievit, F. M., Florczyk, S. J., Leung, M. C., Veiseh, O., Park, J. O., Disis, M. L., & Zhang, M. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.03.062 · Cited by 209
Pinzón‐Daza, M., Garzón, R., Couraud, P., Romero, I., Weksler, B., Ghigo, D., Bosia, A., & Riganti, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02103.x · Cited by 84
Metadata
- Authors
- Mercer, R. W., Tyler, M. A., Ulasov, I. V., & Lesniak, M. S.
- Venue
- BioDrugs
- Published
- 2009
- Volume
- 23
- Issue
- 1
- Pages
- 25-35
- ISSN
- 1173-8804
- PMC
- PMC2669548
- Cited by
- 39
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
